Ganciclovir for injection

Nucleoside antiviral drugs. After entering the cell, this product is rapidly phosphorylated to a monophosphate compound, and then becomes a triphosphate compound through the action of cellular kinase. Its phosphorylation in cells infected with cytomegalovirus is faster than that in normal cells. Ganciclovir can competitively inhibit DNA polymerase and incorporate into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This product has a stronger inhibitory effect on viral DNA polymerase than host cell polymerase. In animal experiments, this product has teratogenic, carcinogenic, immunosuppressive effects and reproductive system toxicity.

Main ingredient: Ganciclovir Chemical name: 9-(1,3-dihydroxy-2-propyloxymethyl)-guanine Molecular formula: C9H12N5O4 Molecular weight: 255.23.

1. It is suitable for the induction and maintenance treatment of cytomegalovirus retinitis in immunodeficient patients (including AIDS patients). 2. It can also be used to prevent cytomegalovirus infection in patients receiving organ transplantation and to prevent cytomegalovirus disease in AIDS patients with positive cytomegalovirus serological test.

1 Induction phase: intravenous drip of 5 mg/kg per body weight, once every 12 hours, each drip for more than 1 hour, the course of treatment is 14 to 21 days, and the dose should be reduced for patients with renal impairment. When the creatinine clearance is 50-69 ml/min, intravenous drip of 2.5 mg/kg every 12 hours; when the creatinine clearance is 25-49 ml/min, intravenous drip of 2.5 mg/kg every 24 hours; when the creatinine clearance is 10-24 ml/min, intravenous drip of 1.25 mg/kg every 24 hours; when the creatinine clearance is <10 ml/min, the drug is given 3 times a week, each time 1.25 mg/kg is given after hemodialysis. 2 Maintenance phase: intravenous drip of 5 mg/kg per body weight, once a day, for more than 1 hour. For patients with impaired renal function, the dosage is adjusted according to the creatinine clearance: when the creatinine clearance is 50-69 ml/min, 2.5 mg/kg is intravenously dripped every 24 hours; when the creatinine clearance is 25-49 ml/min, 1.25 mg/kg is intravenously dripped every 24 hours; when the creatinine clearance is 10-24 ml/min, 0.625 mg/kg is intravenously dripped every 24 hours; when the creatinine clearance is <10 ml/min, the drug is administered 3 times a week, 0.625 mg/kg each time after hemodialysis. 3 Preventive medication: intravenous drip of 5 mg/kg per body weight, the drip time is at least 1 hour, once every 12 hours, for 7 to 14 consecutive days; followed by 5 mg/kg, once a day, for a total of 7 days. When this product is administered by intravenous drip, the preparation method is as follows: first determine the dosage based on the patient's weight, dissolve it with an appropriate amount of water for injection or sodium chloride injection to a concentration of 50 mg/ml, and then inject it into 100 ml of sodium chloride injection, 5% glucose injection, compound sodium chloride injection or compound sodium lactate injection. The concentration of the drip solution must not be greater than 10 mg/ml.

1..Common adverse reactions include bone marrow suppression. After taking the drug, about 40% of patients have a neutrophil count reduced to less than 1000/mm3, and about 20% of patients have a platelet count reduced to less than 50,000/mm3. In addition, anemia may occur. 2. Central nervous system symptoms such as mental abnormalities, tension, tremors, etc., with an incidence of about 5%, and occasional coma, convulsions, etc. 3..Rash, itching, drug fever, headache, dizziness, dyspnea, nausea, vomiting, abdominal pain, loss of appetite, abnormal liver function, gastrointestinal bleeding, arrhythmia, increased or decreased blood pressure, hematuria, increased blood urea nitrogen, hair loss, decreased blood sugar, edema, general discomfort, increased creatinine, eosinophilia, local pain after injection, phlebitis, etc. may occur; AIDS patients with cytomegalovirus retinitis may experience retinal detachment.

It is contraindicated for patients who are allergic to this product or acyclovir.

1. When this product is used together with drugs that affect the hematopoietic system, bone marrow suppressants and radiotherapy, the inhibitory effect on the bone marrow can be enhanced. 2. When this product is used together with nephrotoxic drugs (such as amphotericin B, cyclosporine), it may enhance renal damage, reduce the renal excretion of this product and cause toxic reactions. 3. When used together with zidovudine, it can enhance the toxicity to the hematopoietic system and must be used with caution. 4. When used together with didanosine or used successively, the area under the drug-time curve of the latter can be significantly increased (increased by 72% to 111%), and the renal clearance of the two remains unchanged. 5. When this product is used together with imipenem and cilastatin, systemic convulsions may occur. 6. When used together with probenecid or drugs that inhibit renal tubular secretion, the renal clearance of this product can be reduced by about 22%, and its area under the drug-time curve can be increased by about 53%, which is prone to toxic reactions. 7. Avoid using it together with dapsone, pentamidine, flucytosine, vinblastine, doxorubicin, trimethoprim, sulfonamides and nucleoside drugs.

Sealed, store in a dry place.

250mg

Ma'anshan Fengyuan Pharmaceutical Co., Ltd.

• Founded in:

  2008-06-26

• Address:

  No. 1503, Meishan Road, Economic and Technological Development Zone, Ma'anshan City, Anhui Province

• Tax NO.:

  913405006758985090

• Registered Funds:

  145.5 million yuan

• Email:

  Log in to view